Vetter offers two new clinical syringe packages

Earlier syringe development may cut time-to-market and increase clinical trial appeal

Vetter, a German contract development and manufacturing organisation (CDMO), is offering two clinical syringe packages that will make it easier to start syringe development earlier in the drug development process and cut up to 18 months off time-to-market.

The Standard Package provides an all-inclusive service, starting with materials selection – the best combination of syringe, needle and stopper to meet a compound’s requirements – and continuing to cGMP clinical syringe filling.

The Starter Package commences with the same materials selection, proceeds through feasibility testing and regulatory consultation, and ends with a non-cGMP stability run. Even if not planning an immediate launch in a syringe, predetermining syringe feasibility enables a nimble response to a change in market or business priorities; it may also enhance product attractiveness if seeking to out-license. Both packages are customisable to the needs of the compound and to the business goals of the innovator.

Traditionally, companies begin syringe development only after vials near completion of Phase III. It typically takes up to two years to complete the transition to syringes, from packaging selection through validation/registration runs. Starting syringe development earlier can cut transition time by as much as 18 months, depending upon when syringe work begins and the complexity of the compound.

Launching directly in a prefilled syringe, when appropriate, rather than vial-only first, can differentiate products in a marketplace seeking patient-friendly systems. Moreover, it may be easier to recruit medical clinics for trials that use prefilled syringes, since they require less handling and preparation than vials and have reduced risk of needle-stick injuries.

'As the market moves toward prefilled syringes, we wanted to enable our customers to get an earlier start on syringe development, when it suits their compound and their business goals,' said Peter Soelkner, Managing Director of Vetter.

'Our new clinical syringe packages, coupled with the development expertise of our scientists and the advanced technology of our facilities, give our customers an easier way to pursue syringe work earlier.'

Featured Companies

Vetter Pharma International (more information, website)